期刊文献+

抗病毒药替比夫定的合成工艺研究 被引量:2

Synthetic process of telbivudine,an antivirus agent
原文传递
导出
摘要 目的改进抗病毒药替比夫定(telbivudine)的合成工艺。方法以L-阿拉伯糖为起始原料,经加成环合、取代、环合异构、保护卤代、脱卤、水解共6步反应合成目标化合物。结果与结论目标化合物的结构经1H-NMR、IR、MS谱确证。改进后的工艺无需柱色谱纯化,成本低廉,操作简便,适合工业化生产,总收率可达32.6%。 Aim To improve the synthetic process of telbivudine, an anfivirus drug. Methods The title compound was synthesized from L-arabinose via addition and cyclization, substitution, cyclization and isomerization,protection and halogenation, debalogenation,hydrolysis added up to six steps. Results and contusion The structure of telbivudine was confirmed by ^1 H-NMR, IR and MS. The improved process is suitable for industrial preparation and more practicaI owing to its advantages of low cost, convenient operations without column chromatography and good yield of 32.6%.
出处 《中国药物化学杂志》 CAS CSCD 2009年第1期39-41,共3页 Chinese Journal of Medicinal Chemistry
关键词 化学合成 工艺改进 抗病毒药物 替比夫定 chemical synthesis process improvement antivirus drug telbivudine
  • 相关文献

参考文献6

  • 1刘晓东,胡春.替比夫定(telbivudine)[J].中国药物化学杂志,2007,17(5):335-335. 被引量:12
  • 2许洁,陆志檬.替比夫定治疗慢性乙型肝炎的进展[J].中华肝脏病杂志,2006,14(12):958-959. 被引量:37
  • 3STORER R,MOSSA A, WANG J Y, et al. Synthesis of beta-L-2-deoxy-nucleosides from furanoses and pryanoses via a chloro-sugar and anhydro-l-furanosylnucleobase intermediates as potential antiviral and an- tineoplastic agents: WO, 2005/003374 [ P ]. 2005 - 01 - 13.
  • 4IIZUKA H, TOGASHI K, SUZUKI T, et al. Processes for the synthesis of L-nucleoside derivatives from L- arainoaminooxazoline : WO, 2002/44194 [ P ]. 2002 - 06 - 06.
  • 5GOSSELIN G, IMBACH J, BRYANT M L, et al. Preparation ofβ-L-2'-deoxynucleosides for the treatment of hepatitis B:WO, 2000/09531 [ P ] 2000 - 02 - 24.
  • 6HIDEHITO U, EMIKO O, KEIKO S, et al. Synthesis and properties of mirrorimage DNA [ J ]. Nucleic Acids Res, 1992,20( 13 ) :3325 - 3332.

二级参考文献18

  • 1许洁,陆志檬.替比夫定治疗慢性乙型肝炎的进展[J].中华肝脏病杂志,2006,14(12):958-959. 被引量:37
  • 2Bryant ML,Bridges EG,Placidi L,et al.Antiviral L-nucleosides specific for hepatitis B virus infection.Antimicrob Agents Chemother,2001,45:229-235.
  • 3Zhou XJ,Lloyd DM,Cbao GC,et al.Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.J Clin Pharmacol,2006,46:275-281.
  • 4Zhou XJ,Lim SG,Lloyd DM,et al.Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection:pharmacodynamic implications.Antimicrob Agents Chemother,2006,50:874-879.
  • 5Lai,CL,Lim SG.A dose finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.Hepatology,2004,40:719-726.
  • 6Lai CL,Leung N,Teo EK,et al.A l-year trial of telbivudine,lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology,2005,129:528-536.
  • 7Lai CL,Leung N,Teo EK,et al.Phase Ⅱb Extended-Treatment Trial of Telbivudine (LdT) vs.Lamivudine vs Combination Treatment in Hepatitis B Patients:Two-Year Results.DDW,Chicago,IL,USA.2005.
  • 8Lai CL,Gane E,Thongsawat S,et al.Telbivudine (LdT) vs.Lamivudine in the treatment of Chronic Hepatitis B:Results from GLOBE,an international Phase Ⅲ TriaL.Shanghai-Hong Kong International Liver Congress; 2006.
  • 9Lai CL,Gane E,Hsu CW,et al.Two-Year Results from the GLOBE Trial in Patients with Hepatitis B:Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine.Hepatology,2006,44(4 Suppl 1):222A.
  • 10Hou JL,Yin YK,Xu DZ,et al.A phase Ⅲ comparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in Chinese patients:first year results.Presented at:Shanghai-Hong Kong International Liver Congress; 2006.

共引文献47

同被引文献9

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部